.... 2025 Subclinical inflammation Inflammation Transplant Biomarker Kidney allograft rejection remains an important cause of graft loss in the long term [ 1 ], and its early detection and correct treatment are essential to improve graft survival. Due to the high rate of rejection...

...Mengmeng Pu; Huanhuan Zhao; Silei Xu; Xiaohui Gu; Qiang Feng; Peng Huang Introduction: Sepsis-associated acute kidney injury (SA-AKI) is a common complication of sepsis. miR-340-5p has been identified as an effective biomarker of various human diseases. As the downstream target, the involvement...

... is to identify patients at higher risk of developing CKD to initiate therapy before CKD develops (primary prevention of CKD) and to identify patients with CKD and high risk of progression or death, in order to intensify therapy. We now discuss recent advances in biomarkers that may contribute...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Biomarker Uromodulin Fibrosis Chronic kidney disease Furosemide stress test Interstitial fibrosis and tubular atrophy (IFTA) are common findings on biopsy...

... eGFR and albuminuria. Key Messages: Novel biomarkers of kidney tubular health consistently associate with MAKEs, above and beyond baseline eGFR, albuminuria, and other CKD risk factors. Tubular markers may provide new opportunities to improve kidney prognosis, drug dosing, and monitoring for adverse...

...Ibrahim Sandokji; Yunwen Xu; Michelle Denburg; Susan Furth; Alison G. Abraham; Jason H. Greenberg Background: Due to the complexity of chronic kidney disease (CKD) pathophysiology, biomarkers representing different mechanistic pathways have been targeted for the study and development of novel...

... biomarkers in the early diagnosis and treatment response monitoring of human patients with AKI. Key Messages: Experimental and clinical evidence suggests the critical role of ER in the pathogenesis and progression of AKI, and ER is a novel target in AKI therapy. Currently, there is no treatment for AKI...

...Jean-Maxime Côté; Liam Lyons; Patrick J. Twomey; Ted J. Fitzgerald; Jia Wei Teh; John Holian; Aisling O’Riordan; Alan Watson; Michelle Clince; Fahad Malik; John O’Regan; Patrick T. Murray Introduction: The use of novel kidney injury biomarkers has been shown to improve diagnostic assessment...

..., but the basic pathobiology of FGF23 in AKI is rather sparse. Conversely, preclinical data supporting a pathogenic role of αKlotho in AKI are strong, but the human data are still being generated. This pair of substances can potentially serve as diagnostic and prognostic biomarkers. FGF23 blockade and αKlotho...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Biomarker Tubule Albuminuria Acute kidney injury Acute kidney injury (AKI) is a common clinical syndrome that plays an important role in the nonlinear progression...

... recognized, the reported incidence of ARC is highly variable, and more evidence is necessary to identify risk factors associated with its development [ 3, 5, 6 ]. One possible explanation for the variable reported incidence of ARC is the different biomarkers and equations that have been utilized...

...Esmeralda Castillo-Rodriguez; Raul Fernandez-Prado; Catalina Martin-Cleary; Maria Soledad Pizarro-Sánchez; Maria Dolores Sanchez-Niño; Ana Belen Sanz; Beatriz Fernandez-Fernandez; Alberto Ortiz The current categorization of chronic kidney disease (CKD) is based on biomarkers of the glomerular...

... finding of oliguria, we explore the relationship between the functional biomarker of renal injury (oliguria) with the increasing number of markers of renal injury to see if this combination may aid in risk stratification. [email protected] 21 03 2016 23 06 2016 10 8 2016...

... to become new diagnostic biomarkers of AKI. Further investigation will identify the key pathogenic miRNAs in various types of AKI and test miRNA-based therapeutics and diagnosis. [email protected] 25 02 2016 2 05 2016 21 6 2016 © 2016 S. Karger AG, Basel 2016 Copyright / Drug...